Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
| ▸ | LPO | P22079 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31332794 | 0.77 | NPC1 (0.33) | CYP11B2ADRB3TMEM97HRH3NR4A2 | |
| SCHEMBL31332848 | 0.73 | RAD52 (0.38) | NR4A2BRD4MEN1ALDH1A1KMT2A | |
| SCHEMBL12724434 | 0.73 | ALDH1A1 (0.41) | NR4A2BRD4ALDH1A1NOTUMLPO | |
| SCHEMBL31333014 | 0.73 | — | — | |
| SCHEMBL31333016 | 0.72 | NR4A2 (0.38) | CYP11B2NR4A2BRD4ALDH1A1KMT2A | |
| SCHEMBL31333053 | 0.72 | NR4A2 (0.38) | CYP11B2NR4A2BRD4ALDH1A1KMT2A | |
| SCHEMBL31332845 | 0.72 | NR4A2 (0.38) | NR4A2BRD4MEN1ALDH1A1KMT2A | |
| SCHEMBL31332856 | 0.71 | RAD52 (0.34) | NR4A2BRD4MEN1ALDH1A1KMT2A | |
| SCHEMBL31332919 | 0.70 | — | — | |
| SCHEMBL31332867 | 0.70 | ALDH1A1 (0.38) | CYP11B2NR4A2BRD4ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709374-A2 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024233885-A2 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | HCN2, HCN1, HCN4 | CNR2 121/4885CYP11B2 268/4885ADRB3 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.